WO2003010135A1 - Nouveaux derives de l'acide phenylpropionique - Google Patents

Nouveaux derives de l'acide phenylpropionique Download PDF

Info

Publication number: WO2003010135A1
Authority: WO; WIPO (PCT)
Prior art keywords: acid derivatives; phenylpropionic acid; integrin; hydrogen; participates
Prior art date: 2001-07-26

Application number

PCT/JP2002/007543

Other languages

English (en)

French (fr)

Inventor

Akira Chiba

Kazuyuki Sagi

Toshihiko Yoshimura

Tatsuya Okuzumi

Hiroyuki Izawa

Masahiro Murata

Original Assignee

Ajinomoto Co., Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-26

Filing date

2002-07-25

Publication date

2003-02-06

2002-07-25 Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.

2002-07-25 Priority to JP2003515495A priority Critical patent/JP4164871B2/ja

2003-02-06 Publication of WO2003010135A1 publication Critical patent/WO2003010135A1/ja

2004-01-26 Priority to US10/763,237 priority patent/US7193108B2/en

Links

YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 title abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
108010041012 Integrin alpha4 Proteins 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
108010044426 integrins Proteins 0.000 abstract 1
102000006495 integrins Human genes 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PCT/JP2002/007543 2001-07-26 2002-07-25 Nouveaux derives de l'acide phenylpropionique WO2003010135A1 (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
JP2003515495A JP4164871B2 (ja)	2001-07-26	2002-07-25	新規フェニルプロピオン酸誘導体
US10/763,237 US7193108B2 (en)	2001-07-26	2004-01-26	Phenylpropionic acid derivatives

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001225749		2001-07-26
JP2001-225749		2001-07-26

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US10/763,237 Continuation US7193108B2 (en)	2001-07-26	2004-01-26	Phenylpropionic acid derivatives

Publications (1)

Publication Number	Publication Date
WO2003010135A1 true WO2003010135A1 (fr)	2003-02-06

Family

ID=19058688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/007543 WO2003010135A1 (fr)	2001-07-26	2002-07-25	Nouveaux derives de l'acide phenylpropionique

Country Status (3)

Country	Link
US (1)	US7193108B2 (ja)
JP (1)	JP4164871B2 (ja)
WO (1)	WO2003010135A1 (ja)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004083170A3 (en) *	2003-03-19	2005-04-28	Ciba Sc Holding Ag	Compounds, a process for their preparation and their use as dyes and pigments
US6960597B2 (en)	2000-06-30	2005-11-01	Orth-Mcneil Pharmaceutical, Inc.	Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
WO2007145282A1 (ja) *	2006-06-14	2007-12-21	Toray Industries, Inc.	アレルギー性皮膚炎の治療又は予防剤
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
CN101472581B (zh) *	2006-06-20	2011-06-08	东丽株式会社	白血病的治疗或预防药
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
WO2013116287A1 (en)	2012-01-31	2013-08-08	Genentech, Inc.	Anti-ig-e m1' antibodies and methods using same
EP3095463A2 (en)	2008-09-16	2016-11-23	F. Hoffmann-La Roche AG	Methods for treating progressive multiple sclerosis
EP3130349A1 (en)	2004-06-04	2017-02-15	Genentech, Inc.	Method for treating multiple sclerosis
WO2017062682A2 (en)	2015-10-06	2017-04-13	Genentech, Inc.	Method for treating multiple sclerosis
US10450379B2 (en)	2005-11-15	2019-10-22	Genetech, Inc.	Method for treating joint damage
US11116760B2 (en)	2018-10-30	2021-09-14	Gilead Sciences, Inc.	Quinoline derivatives
US11174256B2 (en)	2018-10-30	2021-11-16	Gilead Sciences, Inc.	Imidazopyridine derivatives
US11179383B2 (en)	2018-10-30	2021-11-23	Gilead Sciences, Inc.	Compounds for inhibition of α4β7 integrin
US11224600B2 (en)	2018-10-30	2022-01-18	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en)	2019-08-14	2023-02-14	Gilead Sciences, Inc.	Compounds for inhibition of α4 β7 integrin

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1288205E (pt) *	2000-08-18	2011-05-06	Ajinomoto Kk	Novos derivados de fenilalanina
DE60124573T2 (de) *	2000-09-29	2007-06-21	Ajinomoto Co., Inc.	Neue phenylalanin-derivate
JP4452899B2 (ja) *	2001-12-13	2010-04-21	味の素株式会社	新規フェニルアラニン誘導体
EP1595870B1 (en)	2003-02-20	2015-09-23	Ajinomoto Co., Inc.	Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
CN1761650A (zh) *	2003-03-19	2006-04-19	西巴特殊化学品控股有限公司	化合物,其制备方法及其作为染料和颜料的应用
ES2451140T3 (es) *	2003-11-27	2014-03-26	Ajinomoto Co., Inc.	Cristal de derivado de fenilalanina y método para su producción
KR20110098980A (ko) *	2003-12-22	2011-09-02	아지노모토 가부시키가이샤	신규한 페닐알라닌 유도체
CA2714335A1 (en)	2007-02-20	2008-08-28	Merrimack Pharmaceuticals, Inc.	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2008333635A1 (en) *	2007-12-03	2009-06-11	Merck Patent Gmbh	Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders
ES2525065T3 (es)	2008-04-11	2014-12-17	Merrimack Pharmaceuticals, Inc.	Ligadores de seroalbúmina humana y sus conjugados
WO2010059315A1 (en) *	2008-11-18	2010-05-27	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
MX2014004319A (es)	2011-10-17	2015-05-15	Univ Muenster Wilhelms	Valoracion del riesgo de pml (leucoencefalopatia multifocal progresiva) y metodos basados en la misma.
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
CN115806488A (zh) *	2022-12-28	2023-03-17	南京工业大学	一种对环烷醇进行开环烯丙基化的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996015096A1 (en) *	1994-11-15	1996-05-23	Bayer Corporation	Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
WO1999010313A1 (en) *	1997-08-22	1999-03-04	F.Hoffmann-La Roche Ag	N-aroylphenylalanine derivatives
WO1999036393A1 (en) *	1998-01-20	1999-07-22	Tanabe Seiyaku Co., Ltd.	INHIBITORS OF α4 MEDIATED CELL ADHESION
WO2000005223A2 (en) *	1998-07-23	2000-02-03	Astrazeneca Ab	Heterocyclic derivatives and their use as integrin inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4788939B2 (ja) *	1999-11-18	2011-10-05	味の素株式会社	新規フェニルアラニン誘導体
PT1288205E (pt) *	2000-08-18	2011-05-06	Ajinomoto Kk	Novos derivados de fenilalanina

2002
- 2002-07-25 WO PCT/JP2002/007543 patent/WO2003010135A1/ja active Application Filing
- 2002-07-25 JP JP2003515495A patent/JP4164871B2/ja not_active Expired - Fee Related
2004
- 2004-01-26 US US10/763,237 patent/US7193108B2/en not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996015096A1 (en) *	1994-11-15	1996-05-23	Bayer Corporation	Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
WO1999010313A1 (en) *	1997-08-22	1999-03-04	F.Hoffmann-La Roche Ag	N-aroylphenylalanine derivatives
WO1999036393A1 (en) *	1998-01-20	1999-07-22	Tanabe Seiyaku Co., Ltd.	INHIBITORS OF α4 MEDIATED CELL ADHESION
WO2000005223A2 (en) *	1998-07-23	2000-02-03	Astrazeneca Ab	Heterocyclic derivatives and their use as integrin inhibitors

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6960597B2 (en)	2000-06-30	2005-11-01	Orth-Mcneil Pharmaceutical, Inc.	Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
WO2004083170A3 (en) *	2003-03-19	2005-04-28	Ciba Sc Holding Ag	Compounds, a process for their preparation and their use as dyes and pigments
EP3130349A1 (en)	2004-06-04	2017-02-15	Genentech, Inc.	Method for treating multiple sclerosis
US10654940B2 (en)	2005-11-15	2020-05-19	Genentech, Inc.	Method for treating joint damage
US10450379B2 (en)	2005-11-15	2019-10-22	Genetech, Inc.	Method for treating joint damage
JP5115478B2 (ja) *	2006-06-14	2013-01-09	東レ株式会社	アレルギー性皮膚炎の治療又は予防剤
CN101472580B (zh) *	2006-06-14	2011-08-24	东丽株式会社	过敏性皮炎的治疗或预防药
KR101353707B1 (ko)	2006-06-14	2014-01-20	도레이 카부시키가이샤	알레르기성 피부염의 치료 또는 예방제
US9162988B2 (en)	2006-06-14	2015-10-20	Toray Industries, Inc.	Therapeutic or prophylactic agent for allergic dermatitis
WO2007145282A1 (ja) *	2006-06-14	2007-12-21	Toray Industries, Inc.	アレルギー性皮膚炎の治療又は予防剤
CN101472581B (zh) *	2006-06-20	2011-06-08	东丽株式会社	白血病的治疗或预防药
EP4364800A2 (en)	2008-09-16	2024-05-08	F. Hoffmann-La Roche AG	Methods for treating progressive multiple sclerosis
EP3747464A1 (en)	2008-09-16	2020-12-09	F. Hoffmann-La Roche AG	Methods for treating progessive multiple sclerosis using an anti-cd20 antibody
EP3095463A2 (en)	2008-09-16	2016-11-23	F. Hoffmann-La Roche AG	Methods for treating progressive multiple sclerosis
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
WO2013116287A1 (en)	2012-01-31	2013-08-08	Genentech, Inc.	Anti-ig-e m1' antibodies and methods using same
WO2017062682A2 (en)	2015-10-06	2017-04-13	Genentech, Inc.	Method for treating multiple sclerosis
EP4491227A2 (en)	2015-10-06	2025-01-15	F. Hoffmann-La Roche AG	Method for treating multiple sclerosis
US11116760B2 (en)	2018-10-30	2021-09-14	Gilead Sciences, Inc.	Quinoline derivatives
US11174256B2 (en)	2018-10-30	2021-11-16	Gilead Sciences, Inc.	Imidazopyridine derivatives
US11179383B2 (en)	2018-10-30	2021-11-23	Gilead Sciences, Inc.	Compounds for inhibition of α4β7 integrin
US11224600B2 (en)	2018-10-30	2022-01-18	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
US12053462B2 (en)	2018-10-30	2024-08-06	Gilead Sciences, Inc.	Quinoline derivatives
US11578069B2 (en)	2019-08-14	2023-02-14	Gilead Sciences, Inc.	Compounds for inhibition of α4 β7 integrin

Also Published As

Publication number	Publication date
JPWO2003010135A1 (ja)	2004-11-18
US7193108B2 (en)	2007-03-20
JP4164871B2 (ja)	2008-10-15
US20040236147A1 (en)	2004-11-25

Legal Events

Date	Code	Title	Description
2003-02-06	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
2003-02-06	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-03-06	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-04-02	121	Ep: the epo has been informed by wipo that ep was designated in this application
2003-12-15	WWE	Wipo information: entry into national phase	Ref document number: 2003515495 Country of ref document: JP
2004-01-26	WWE	Wipo information: entry into national phase	Ref document number: 10763237 Country of ref document: US
2004-06-03	REG	Reference to national code	Ref country code: DE Ref legal event code: 8642
2004-09-29	122	Ep: pct application non-entry in european phase

Publication	Publication Date	Title
WO2003010135A1 (fr)	2003-02-06	Nouveaux derives de l'acide phenylpropionique
CA2359810A1 (en)	2001-07-05	Process for the preparation of pure citalopram
ATE312114T1 (de)	2005-12-15	Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate
HK1089444A1 (en)	2006-12-01	Dihydropteridinones, method for the production and use thereof in the form of drugs
EP2266623A3 (en)	2011-10-12	Prodrugs containing novel bio-cleavable linkers
ATE427311T1 (de)	2009-04-15	(r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
UA84407C2 (en)	2008-10-27	Acetyl 2-hydroxy-1,3 diaminoalkanes
UA82980C2 (ru)	2008-06-10	Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза
WO2001085671A3 (de)	2002-04-11	Anthranylamide und deren verwendung als arzneimittel
NZ320580A (en)	1998-12-23	Tricyclic compounds, preparation and pharmaceutical compositions thereof
ATE289810T1 (de)	2005-03-15	Ecteinascidinderivate
EP1132379A4 (en)	2005-02-16	NOVEL THIOL DERIVATIVES, METHOD FOR PRODUCING THE SAME, AND USE THEREOF
ATE394379T1 (de)	2008-05-15	4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung
EP1122252A4 (en)	2002-06-26	CONDENSED HEREROCYCLIC NITROGEN COMPOUNDS; MANUFACTURING PROCESS AND AGENTS CONTAINING THEM
WO2003033506A1 (fr)	2003-04-24	Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
BG107050A (en)	2003-05-30	Method for the preparation of citalopram
ATE345787T1 (de)	2006-12-15	Verwendung von cyclohexenon derivaten zur herstellung eines medikaments für die behandlung von dysurie
DE60107832D1 (en)	2005-01-20	Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
YU38401A (sh)	2005-06-10	Derivati benzofurana, njihova izrada i upotreba
MXPA05012743A (es)	2006-02-13	Composicion de limpieza mejorada.
UA41340C2 (uk)	2001-09-17	Похідні циклогексанкарбонової кислоти, суміш їх ізомерів або окремі ізомери і фізіологічно прийнятні солі і фармацевтична композиція з активністю, що гальмує ферментний комплекс глюкоза-6-фосфатази
WO2004065360A3 (en)	2004-11-11	Piperazine derivatives and their use as synthesis intermediates
MXPA05014127A (es)	2006-02-24	Uso de derivados de biciclo[2.2.1]heptano para la preparacion de composiciones farmaceuticas neuroprotectoras.
AU3590801A (en)	2001-09-17	One-pot synthesis of alkyl 3-cyclopropylamino-2-(2,4-dibromo-3-(difluoromethoxy)benzoyl -2-propenoate as a useful intermediate for antibacterial quinolone medicaments
ES2058458T3 (es)	1994-11-01	Inhibidor de la formacion de la placa dental.